MedTrace Logo

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02748902 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-07-17

No results posted yet for this study

Summary

The purpose of this study is to determine if ingenol mebutate 0.05% gel is safe and effective in treating common warts on the hands.

Conditions

  • Verruca Vulgaris
  • Common Warts

Interventions

DRUG

ingenol mebutate 0.05% gel

Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Neal D. Bhatia, MD

    lead OTHER

Principal Investigators

  • Neal D Bhatia, MD · TCR Medical Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-27
Primary Completion
2017-01-27
Completion
2017-03-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748902 on ClinicalTrials.gov